详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

Fever of unknown origin associated with immune checkpoint inhibitors

71| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

单位： [1]The Second Clinical Medical College, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. [2]Department and Institute of Infectious Disease,Tongji Hospital,Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Disease,Huazhong University of Science and Technology,Wuhan,Hubei,China.

出处：

DOI：

ISSN：

关键词： immune checkpoint inhibitors fever cytokines FUO irAEs

摘要：

Since the approval for the treatment of melanoma in 2014, immune checkpoint inhibitors (ICIs) have revolutionized the therapy pattern across various malignancies. Coinciding with their frequent usage, their adverse effects, including fever, cannot be neglected. In the context of cancer diseases and cancer treatments, fever of unknown origin (FUO), which has long posed a challenge for clinicians in terms of diagnosis and management, brings forth new connotation and significance. In this paper review, we present the concept of ICIs-associated FUO, consider activated immune system and elevated cytokines as common mechanisms by which ICIs induce fever and various immune-related adverse events (irAEs), summarize and compare the primary etiologies of ICI-associated FUO, and compare it with conventional types of FUO.Copyright © 2024 Tong, Zhan, Dong and Xu.

语种：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2023]版：

大类 | 2 区医学

小类 | 2 区免疫学

最新[2025]版：

大类 | 2 区医学

小类 | 2 区免疫学

JCR分区：

出版当年[2022]版：

Q1 IMMUNOLOGY

最新[2023]版：

Q1 IMMUNOLOGY

影响因子： 5.7 最新[2023版] 6.8 最新五年平均 7.3 出版当年[2022版] 8 出版当年五年平均 8.787 出版前一年[2021版] 5.7 出版后一年[2023版]

第一作者：

第一作者单位： [1]The Second Clinical Medical College, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.

共同第一作者：

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Immune Checkpoint Inhibitors Related to Cardiotoxicity [2]Diagnosis and Management of Immune Related Adverse Events (irAEs) in Cancer Immunotherapy [3]Immune checkpoint inhibitors in the treatment of virus-associated cancers [4]Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors [5]Gut microbiome modulates efficacy of immune checkpoint inhibitors [6]Case Report: Cardiac Toxicity Associated With Immune Checkpoint Inhibitors [7]Toxicities associated with immune checkpoint inhibitors: A systematic study [8]免疫检查点抑制剂治疗肿瘤的不良反应及管理策略 [9]Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy [10]Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer